In a groundbreaking review set to reshape public health policies, researchers at the University of Mississippi have presented compelling evidence that ambient air pollution levels deemed safe by current Environmental Protection Agency (EPA) standards may nonetheless pose a significant risk to cardiovascular health. This extensive review, recently published in the scientific journal Environmental Pollution, synthesizes decades of global research, underscoring the urgent need to revisit and potentially lower regulatory thresholds for fine particulate matter, specifically PM2.5.

PM2.5 refers to microscopic particulate matter with a diameter less than 2.5 microns—around 20 times smaller than a human hair—which makes them capable of penetrating deep into the respiratory tract and entering the bloodstream. These particles originate from diverse sources such as vehicular emissions, industrial manufacturing, biomass burning, and dust from agricultural activities. Their diminutive size allows them to circumvent the body’s natural defense mechanisms, reaching vital organs and triggering systemic health effects.

The review meticulously analyzed 95 peer-reviewed studies that addressed cardiovascular impacts related to low-level PM2.5 exposures worldwide. Strikingly, approximately two-thirds of these studies demonstrated significant associations between PM2.5 exposure and adverse cardiovascular outcomes, including heart attacks, strokes, and increased arterial plaque accumulation. Such findings suggest that even concentrations below the EPA’s current allowable limits can compromise cardiovascular function and contribute to disease progression.

One of the most alarming revelations from the review is the heightened vulnerability of specific demographic groups. Older adults, infants, individuals with preexisting heart conditions, socioeconomically disadvantaged communities, and marginalized populations bear a disproportionate burden of the health consequences posed by low-level PM2.5 exposure. The underlying reasons include a combination of biological susceptibility, existing comorbidities, and environmental inequities that result in unequal pollution exposures.

Experts leading the study emphasize that the source of PM2.5 plays a pivotal role in its health impact. Traffic-related pollution, industrial emissions, and rural dust each possess unique chemical compositions and particle characteristics that influence toxicity. For instance, black carbon—a key component of soot prevalent in urban areas—has been linked to respiratory and cardiovascular morbidity. Understanding these nuances is critical for tailoring regulatory actions and mitigation strategies.

Technological advances in air quality monitoring have highlighted the dynamic nature of pollution exposure. Daily fluctuations in PM2.5 concentrations, even within previously considered ‘safe’ ranges, can exacerbate risk. The lack of widespread public awareness regarding these subtleties hampers proactive health protection. Consequently, researchers call for enhanced education campaigns to inform communities about real-time air quality risks and personal protection measures.

Cardiovascular disease remains the leading cause of mortality on a global scale, and these findings carry profound implications for public health. The pathophysiological mechanisms implicate PM2.5 in accelerating atherosclerosis, fostering systemic inflammation, and enhancing thrombogenic potential. These processes collectively escalate the likelihood of acute cardiovascular events. The pervasiveness of PM2.5 exposure across urban, industrial, and rural environments necessitates a broad-reaching response.

Current public health recommendations to mitigate individual risk include monitoring localized air quality indices and adopting practical interventions on high-exposure days. Utilization of high-efficiency particulate air (HEPA) filtration systems within indoor environments, combined with the use of adequately rated masks such as N95 respirators, can substantially reduce personal particulate inhalation. These tools are particularly vital for sensitive populations engaging in outdoor activities during episodes of elevated pollution.

The review underscores the critical interplay between environmental science and clinical health disciplines. Healthcare providers are encouraged to integrate pollution exposure assessments into routine cardiovascular risk evaluations. Furthermore, temporal spikes in air pollution should prompt heightened clinical vigilance among patients with known cardiovascular vulnerabilities.

While treatment modalities for pollution-induced cardiovascular damage remain limited, prevention through regulatory intervention and public engagement is paramount. This study advocates for policy reforms that reflect emerging scientific evidence—ideally, lowering the maximum allowable PM2.5 levels to afford more comprehensive protection for population health. Robust air quality enforcement accompanied by community education initiatives constitutes the frontline defense.

Mississippi’s unique environmental landscape, marked by a blend of rural, industrial, and urban pollution sources, exemplifies the broader challenges in managing fine particulate exposure. Researchers at the University of Mississippi have specifically documented elevated black carbon concentrations across various locations within the state, correlating these findings with increased respiratory admissions. Such regional data, when synthesized with global research, bolster the call for targeted policy improvements.

This collective body of work spotlights the critical need for multi-sectoral collaboration spanning environmental regulation, healthcare, urban planning, and public advocacy. Addressing the insidious cardiovascular risks posed by low-level PM2.5 pollution demands concerted efforts to enhance air quality monitoring infrastructure, refine healthcare response frameworks, and cultivate informed, empowered communities.

Ultimately, the path forward rests on reimagining air quality standards rooted in rigorous health evidence. By recognizing and acting upon the risks associated with fine particulate pollution at even low concentrations, society can better safeguard cardiovascular health and reduce the burden of pollution-related morbidity on a global scale.

---

Subject of Research: Health impacts of low-level ambient fine particulate matter (PM2.5) exposure and cardiovascular outcomes

Article Title: A systematic review of low-level ambient fine particulate matter (PM2.5) exposures and adverse cardiovascular health outcomes

Web References:

• EPA Air Quality Basics: https://www.epa.gov/pm-pollution/particulate-matter-pm-basics
• EPA Air Pollution and Cardiovascular Disease: https://www.epa.gov/air-research/air-pollution-and-cardiovascular-disease-basics
• WHO Cardiovascular Diseases Overview: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1

References:
University of Mississippi Review in Environmental Pollution, DOI: 10.1016/j.envpol.2026.127978

Image Credits: Photo illustration by John McCustion/University Marketing and Communications

Keywords: Air pollution, PM2.5, cardiovascular health, fine particulate matter, environmental toxicology, public health, pollution regulation, black carbon, respiratory health, environmental epidemiology, pollution exposure, air quality monitoring

Cardiovascular disease remains the world’s biggest killer, responsible for millions of deaths every year. Most heart attacks and strokes can be traced back to a slow-moving process that begins decades before symptoms appear. This process, known as atherosclerosis, causes fatty deposits to build up inside arteries, gradually reducing blood flow and increasing the risk of […]

The post New Way to Control Dangerous Artery Plaques in Heart Disease appeared first on Knowridge Science Report.

Heart failure following myocardial infarction has long presented a formidable challenge to clinicians worldwide. Despite advances in acute cardiac care, the progression from initial infarction to chronic heart dysfunction remains frequent and devastating. Recent groundbreaking research from The University of Osaka, Japan, has unveiled a promising multipronged therapeutic strategy that leverages the power of mRNA technology to repair the heart after injury. This innovative approach, detailed in the journal Small Science, introduces a sophisticated delivery system based on polyplex nanomicelles to simultaneously administer multiple therapeutic mRNAs directly into damaged heart tissue.

Myocardial infarction precipitates a complex pathological cascade characterized by inflammation, cardiomyocyte death, fibrotic scar formation, and impaired vascularization. These processes collectively undermine cardiac contractility and structural integrity, eventually leading to heart failure. Traditional therapeutic modalities have largely targeted isolated components of this cascade, often rendering limited efficacy due to the multifaceted nature of post-infarction remodeling. The challenge lies in addressing the intricate interplay between cell death, extracellular matrix remodeling, and neovascularization simultaneously, a feat that the current study aims to achieve.

The research team employed a nanotechnology-based delivery vehicle termed polyplex nanomicelles—engineered polymeric carriers designed to protect and transport mRNA molecules efficiently while facilitating their targeted uptake by cardiac cells. By harnessing these nanomicelles, the scientists could convey a cocktail of five distinct mRNAs encoding proteins critical to various repair mechanisms. This multi-mRNA cargo was administered in a controlled manner into the myocardium of a murine heart failure model induced by ischemic injury.

A key advantage of this polyplex nanomicelle system is its ability to overcome the inherent instability and rapid degradation of naked mRNA in vivo. The nanomicelles form condensed complexes with mRNA strands, shielding them from enzymatic breakdown while ensuring sustained release and translation into functional proteins within the cardiac microenvironment. This delivery technology not only amplifies therapeutic efficacy but also minimizes off-target effects and immune activation that typically complicate gene therapy approaches.

The functional proteins encoded by the co-delivered mRNAs orchestrate complementary reparative actions in the infarcted myocardium. They promote angiogenesis, the process of new blood vessel formation essential for supplying oxygen and nutrients to regenerating tissue. Simultaneously, these factors inhibit fibrotic scar deposition by modulating fibroblast activity, thus preserving myocardial compliance and contractile function. Additionally, by fostering cardiomyocyte survival and proliferation, they directly counteract cell loss and support myocardial regeneration.

Experimental results from the murine heart failure models were striking. Treated animals exhibited marked improvements in left ventricular ejection fraction, indicating enhanced cardiac contractility. Histological analyses revealed thicker myocardial walls and reduced scar tissue compared to controls, underscoring the structural benefits of the therapy. Importantly, the formation of functional capillary networks was significantly increased, facilitating improved perfusion and metabolic support for the rehabilitated myocardium.

This integrative strategy also translated into improved survival rates and prolonged cardiac function preservation in the treated cohort. The synergy achieved by addressing multiple pathological targets simultaneously surpasses the outcomes of monotherapy approaches, underscoring the necessity of multifunctional intervention in post-infarction cardiac care. The early timing of therapy post-infarction proved critical, enabling attenuation of maladaptive remodeling cascades before irreversible damage ensued.

Scientifically, this work represents a significant advance in the burgeoning field of regenerative medicine, particularly within the context of mRNA therapeutics. By demonstrating the feasibility and efficacy of delivering multiplexed mRNA payloads via nanomicelles, the study paves the way for future translational research and clinical trials. This platform offers adaptability to incorporate additional or alternative mRNAs tailored to specific injury profiles or patient needs, representing a customizable cardiac repair toolkit.

Considering the global burden of cardiovascular disease and heart failure, the implications of this technology are profound. Beyond myocardial infarctions, similar multipronged mRNA delivery systems may find applications in other ischemic or degenerative cardiac conditions. The potential for mRNA-based regenerative therapies to supplant or complement existing treatments heralds a new era where targeted molecular repair can be achieved with unprecedented precision and efficacy.

As mRNA therapeutics gain momentum in diverse clinical realms, including oncology and infectious diseases, their deployment in cardiology exemplifies the expanding horizons of this versatile modality. The Osaka team’s innovative polyplex nanomicelle delivery system underscores how integrating advanced biomaterials science with molecular biology can overcome longstanding hurdles in tissue regeneration.

In conclusion, the study “Nanomicelle-Based Multi-mRNA Delivery Promotes Cardiac Repair After Myocardial Infarction” exemplifies a pioneering step toward bespoke regenerative therapies that comprehensively address the multifactorial nature of cardiac injury. By fostering coordinated repair mechanisms through simultaneous multi-mRNA administration, this work charts a promising path to improving outcomes for millions suffering from heart failure worldwide. Future research will be essential to refine dosing strategies, investigate long-term safety, and ultimately translate these findings into human clinical practice.

Subject of Research: Animals

Article Title: Nanomicelle-Based Multi-mRNA Delivery Promotes Cardiac Repair After Myocardial Infarction

News Publication Date: 23-May-2026

Web References: http://dx.doi.org/10.1002/smsc.20250052

References: DOI: 10.1002/smsc.20250052

Image Credits: 2026, Kazuma Handa et al., Nanomicelle-Based Multi-mRNA Delivery Promotes Cardiac Repair After Myocardial Infarction, Small Science

Keywords: Cardiology, Heart failure, Heart muscle, Myocardium, Cardiac function, Contractility, Myocardial infarction

In a groundbreaking scientific endeavor poised to reshape psychological assessments in China, researchers have embarked on adapting the Snyder Adult Dispositional Hope Scale for use among older adults suffering from coronary heart disease. This work, published in the eminent journal BMC Geriatrics in 2026, transcends cultural and linguistic barriers by carefully translating and validating a tool that measures hope—a powerful psychological construct intimately linked to health outcomes in chronic disease populations.

Hope, often viewed as a beacon of positive expectancy even in adversity, is fundamentally tied to motivation and goal pursuit. The Snyder scale operationalizes hope by parsing it into agency—the motivational component that propels individuals forward—and pathways, which reflect one’s perceived capacity to generate routes to desired goals. While the scale has seen extensive use worldwide, its application in Chinese populations, especially among elderly patients with cardiac conditions, remained uncharted until now.

Given China’s rapid demographic shift toward an aging population burdened with chronic diseases like coronary heart disease, understanding the psychological determinants that influence health trajectories is imperative. The adaptation of psychological instruments like the Snyder Adult Dispositional Hope Scale stands as a pivotal tool for clinicians and researchers to quantify hope reliably and validly, thus paving the way for targeted interventions.

This cross-sectional study meticulously conducted among older Chinese adults with coronary heart disease rigorously evaluated the scale’s psychometric properties. Researchers ensured cultural and linguistic equivalence through iterative translation, back-translation, and expert panel reviews, triangulated with qualitative feedback from patients to capture nuanced understandings of hope within a Chinese cultural context.

Reliability testing centered on internal consistency measures and test-retest reliability to confirm that the instrument yields stable and consistent results over time. Indeed, the adapted scale demonstrated compelling reliability indices, indicating its dependability for repeated use in clinical and research settings. This consistency is crucial, particularly for longitudinal studies tracking psychological resilience and treatment adherence in chronic disease management.

Beyond reliability, validity assessments encompassed several facets—construct validity, convergent and divergent validity—to affirm that the scale genuinely measures the construct of hope and distinguishes it from related constructs such as optimism or self-efficacy. Factor analyses confirmed that the original two-factor structure—agency and pathways—was preserved, thus supporting the scale’s theoretical foundation even in a new cultural milieu.

An intriguing dimension of this research lies in the interplay between hope and clinical variables among older adults with coronary heart disease. Existing literature posits that higher hope levels correlate with improved health behaviors, better psychological well-being, and even physiological outcomes like cardiac function. This study’s findings reinforce and contextualize these associations within a Chinese patient cohort, suggesting that fostering hope could enhance holistic cardiac care.

Importantly, the adaptation process also accounted for age-specific considerations. Cognitive decline, cultural attitudes toward illness and aging, and linguistic subtleties necessitate a bespoke approach when translating psychometric tools for elderly populations. This study navigated these challenges adeptly, ensuring that items were comprehensible, culturally resonant, and appropriate for older adults’ lived experiences.

The broader implications of this validation extend to clinical practice, where the scale can serve as both a screening instrument and a metric for evaluating psychosocial interventions aimed at boosting hope. For healthcare providers, this represents a paradigm shift in integrating psychological measures into standard care to capture patient-centered outcomes that transcend traditional biomedical parameters.

Furthermore, from a research standpoint, the availability of a culturally validated hope scale unlocks new avenues for exploring psychosocial determinants of health in China’s aging population. It fosters cross-cultural comparisons, enriches global health psychology literature, and informs policy-making for mental health resources allocation in chronic disease settings.

Considering coronary heart disease’s status as a leading cause of morbidity and mortality globally, especially in aging populations, the intersection of psychological resilience and cardiac health assumes critical importance. The adaptable and validated hope scale equips clinicians and researchers with a sophisticated instrument to delve deeper into this nexus and devise comprehensive care models.

The study also underscores the methodological rigor essential in adapting psychological instruments. Mere linguistic translation without cultural adaptation risks misinterpretations and invalid conclusions. The authors’ meticulous approach exemplifies best practices, including psychometric evaluations, qualitative validations, and iterative refinements, setting a standard for future cross-cultural scale adaptations.

In synthesizing these complex processes, the study reinforces that hope is universally significant yet culturally nuanced. Instruments measuring intangible psychological constructs must honor these nuances to retain validity and clinical utility, particularly in populations vulnerable to health disparities and psychosocial stressors.

Moreover, as the global medical community increasingly recognizes the mind-heart connection, integrating psychological metrics like hope into routine cardiac care resonates with holistic medicine principles. It bridges biomedical models with psychosocial frameworks, fostering patient-centered care that acknowledges emotional and motivational dimensions impacting recovery and quality of life.

In summary, the adaptation of the Snyder Adult Dispositional Hope Scale into Chinese is a landmark study that enriches psychological assessment tools for older adults with coronary heart disease. Its rigorous validation assures researchers and clinicians of its reliability and accuracy while emphasizing the transformative potential of hope as a therapeutic target.

This work heralds an era where psychological constructs are not peripheral but central to understanding and managing chronic diseases. By capturing hope’s essence within a culturally attuned framework, this research advances both science and compassionate care for one of humanity’s most vulnerable groups—the aging heart patient.

As this tool gains traction in clinical and academic circles, further longitudinal and intervention studies can leverage it to elucidate how fostering hope directly translates into improved cardiovascular outcomes. Such insights will be invaluable in designing psychologically informed, culturally sensitive care pathways that enhance resilience and healthspan among older adults globally.

Ultimately, this adaptation transcends mere scale translation—it embodies the synthesis of psychology, cardiology, and cultural science, illuminating hope’s indelible role in healing hearts and minds alike. Through this pioneering work, researchers are not just measuring hope but empowering patients to envision and strive toward healthier futures.

---

Subject of Research: Adaptation and validation of the Snyder Adult Dispositional Hope Scale in Chinese older adults with coronary heart disease

Article Title: Adaptation of Snyder adult dispositional hope scale into Chinese: a cross-sectional study on reliability and validity test in older adults with coronary heart disease

Article References:
Cheng, Y., Xia, Y., Zhang, W. et al. Adaptation of Snyder adult dispositional hope scale into Chinese: a cross-sectional study on reliability and validity test in older adults with coronary heart disease. BMC Geriatr (2026). https://doi.org/10.1186/s12877-026-07698-y

Image Credits: AI Generated

For a woman in her mid-40s to mid-50s, it arrives without warning. She wakes up, overheated, wondering why it’s so hot in the house—until she sees the thermostat is set for 70 degrees, same as always. Or, she’s midway through a work presentation when heat rises from her chest to her face, and she wonders if the flush on her cheeks is visible to everyone in the room. 

It’s a hot flash—a rite of passage for the majority of women in either perimenopause, the years leading up to menopause, or the years beyond it. Menopause itself is diagnosed after 12 consecutive months without a period, but the hot flashes don’t always get the memo.

Here’s everything doctors currently know about hot flashes.

What is a hot flash, and who gets them?

Hot flashes are a sudden heat flare up often paired with flushed skin and sweating. They don’t usually last long, between a minute and five minutes in duration.

Most women experience a hot flash about four and a half to five years after their last period, Dr. Monica Christmas, an OB/GYN at University of Chicago Medicine and director of its menopause program tells Popular Science. She also is the associate medical director of the nonprofit Menopause Society, which provides healthcare professionals with tools and resources to support women through the transition.

Women have grappled with hot flashes—whether simply annoying or genuinely debilitating—for centuries. In 1582, Dr. Jean Liebault of France was among the first to document the phenomenon. But while we know much more about hot flashes and night sweats than Liebault ever did, one question still stumps experts. 

“What we can’t answer is why doesn’t everybody get them,” Christmas says. “Because everybody doesn’t get them. I have patients that will say, ‘I don’t know,’ if I say, ‘Are you having any hot flashes or night sweats?’ And as soon as they say that, I’m like, ‘You’re not having them.’” 

What’s actually happening inside women’s bodies during a hot flash? 

During a hot flash, a woman might feel like she’s spiking a high fever, but physiologically, that’s not what is happening. As women approach menopause and the ovaries begin to make less estrogen, the brain’s internal thermostat—the hypothalamus—becomes hypersensitive to even small shifts in temperature, Christmas says.

The body “thinks” it’s overheating, even when the actual temperature hasn’t changed much. In response, our bodies try to cool us down. Blood vessels dilate, which is supposed to help dissipate some of that heat, but then that triggers a sweating reflex.

“Many people will say, ‘I feel this out of nowhere, this surge of warmth that typically is from the nipple line up,’” she says. “And then as soon as the heat came on, and I felt like I was internally heated up or on fire, I start to sweat.” 

Related 'Ask Us Anything' Stories

Can you overdose on cough drops? Short answer: Yes.

Why scars never disappear

Why do your joints hurt when it’s cold? We asked a doctor.

What’s a brain freeze and why do they happen?

Why do we even have baby teeth?

Why we have two nostrils instead of one big hole

How do women experience hot flashes differently? 

Exactly how an individual woman experiences hot flashes varies wildly. Some describe very mild symptoms. Others grapple with profuse sweating. Some experience only hot flashes during the day, while some have regular night sweats. About four in five women experience them at some point during the menopause transition, according to the American College of Obstetricians & Gynecologists.

“There’s a lot of variability,” Christmas says. Common triggers include alcohol, caffeine, high-sugar and highly processed foods, along with stress.

Black women also are more likely to experience more severe and longer-lasting symptoms, sometimes up to 11 years, she says. And research also shows that women with more severe, longer-lasting hot flashes and night sweats appear to be at higher risk of cardiovascular disease.

That doesn’t mean treating hot flashes automatically lowers heart risk, Christmas says. But it does reinforce that these women deserve particularly careful attention to blood pressure, cholesterol, and lifestyle. “I want to make sure I’m doing everything possible to minimize that risk,” she says when she treats her patients. 

There’s more to hot flashes than hormonal changes

For decades, the entire process was blamed purely on estrogen loss, Christmas says. But that explanation left some unanswered questions. 

“That doesn’t explain why every menopausal woman doesn’t have night sweats,” she says. “And it also doesn’t quite explain why we can sometimes start to experience them during the perimenopause transition because during perimenopause, people still have some estrogen.” 

Newer research now is telling a more complex story. When the brain recognizes that a woman’s estrogen levels are low, nerve cells in the hypothalamus called KNDy neurons (pronounced “candy”) become overactive, releasing neurotransmitters, which are chemical signals the brain uses to send messages throughout the body. These neurotransmitters include kisspeptin, dynorphin, and neurokinin B. 

“It’s actually those neurotransmitters that seem to have more of an impact on our ability to regulate our internal temperature,” Christmas says. “They’re not hormones.” 

What to do if you get a hot flash

For women in the middle of their hot flash years—along with the 10 percent of menopausal women who continue to experience them—there are treatments. 

Estrogen-based hormone therapy can help, but not every woman, including those with a history of blood clots or breast cancer, can take hormone therapy. 

Fortunately, researchers’ new understanding about the role of KNDy neurons has allowed for new treatments that block the brain signals that trigger hot flashes in the first place. The FDA approved a new drug called Veozah (it’s chemical name is fezolinetant) in 2023. It targets the neurokinin 3 receptor, which plays a key role in regulating body temperature. 

Lynkuet, another drug (with the chemical name elinzanetant), came along in 2025. It blocks both the neurokinin 1 and neurokinin 3 receptors, interrupting the process that triggers hot flashes at two points instead of one. 

Other medications can also provide relief, though weren’t originally developed for hot flashes, Christmas says. Some SSRIs and SNRIs; gabapentin, a neurologic medication; and oxybutynin, used for overactive bladder, are all used off-label for hot flashes and night sweats. 

Cognitive behavioral therapy and hypnosis also have been shown to reduce hot flashes. “I’m menopausal, too, so I know if I’m under a lot of stress or in a stressful situation, I’m going to probably have more hot flashes than not,” Christmas says. 

“So there’s certainly something about being able to calm our central nervous system down that seems to have an impact, too.”

If you’re struggling with hot flashes, Christmas recommends seeing your healthcare provider for help. Treatments are available. What’s more, in some cases, hot flashes or night sweats could signal other issues, including thyroid disorders, cancer, and infections, among others. 

But bottom line, when it comes to hot flashes, you don’t have to sweat them out.

In Ask Us Anything, Popular Science answers your most outlandish, mind-burning questions, from the everyday things you’ve always wondered to the bizarre things you never thought to ask. Have something you’ve always wanted to know? Ask us.

The post What happens inside your body during a hot flash appeared first on Popular Science.